Letter to editor: The efects of dabrafenib and/or trametinib treatment in Braf V600‑mutant glioma: a systematic review and meta-analysis

The systematic review and meta-analysis titled “The Effects of Dabrafenib and/or Trametinib Treatment in BRAF V600-Mutant Glioma” provides a critical evaluation of these targeted therapies for a challenging subset of gliomas. This review is notable for its comprehensive data integration, offering a robust assessment of the efficacy and safety of dabrafenib and trametinib. By focusing on BRAF V600 mutations, it contributes valuable insights into personalized treatment strategies. However, limitations include study heterogeneity and a lack of long-term follow-up data, which hinder the generalizability and complete understanding of treatment effects. Additionally, while the review emphasizes therapeutic potential, it requires a thorough evaluation of adverse effects. Future research should address these limitations by providing more consistent data, longer follow-up, and a balanced view of treatment risks and benefits.